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Abstract
Background: The topic of trastuzumab therapy without chemotherapy in early breast cancer (EBC) has been repeatedly
discussed at international consensus meetings, but is compromised by the lack of solid evidence from clinical studies.
Methods: An observational study database of patients with EBC receiving trastuzumab-containing (neo)adjuvant therapy
was screened to identify those patients who did not receive cytostatic agents.
Results: Of 3935 patients, 232 (6%) were identified who received no chemotherapy, being characterized by older age,
worse performance status, and/or less aggressive histology. Relapse-free survival in this cohort was 84% (95%
confidence interval [CI] 78–89%) at 3 years and 80% (95% CI 74–87%) at 5 years. However, these rates were significantly
worse than those in the group of patients who received chemotherapy (hazard ratio 1.49; 95% CI 1.06–2.09; P = 0.022).
A similar pattern was observed for overall survival, with marginally non-significant inferiority in the group receiving no
chemotherapy (hazard ratio 1.56; 95% CI 1.00–2.44; P = 0.052). Survival rates in patients receiving no chemotherapy
were 93% (95% CI 88–97%) and 87% (95% CI 81–93%) at 3 and 5 years, respectively. These findings were confirmed by
a propensity score analysis accounting for selection bias.
Conclusions: Trastuzumab plus chemotherapy should remain the preferred option in all patients with HER2-positive
EBC with an indication for adjuvant treatment. However, a limited proportion of patients will need an alternative
treatment approach, either because of contraindications or the patient’s preference. In these selected patients,
trastuzumab monotherapy, eventually combined with endocrine agents, might be a reasonable option offering
favorable long-term outcomes by addressing the high-risk profile associated with HER2-positive disease.
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Background
For over a decade, the monoclonal antibody trastuzumab
has been the cornerstone of adjuvant treatment for
HER2-positive early breast cancer (EBC) [1, 2]. Based on
results from four large randomized trials [3–6], com-
bined treatment with trastuzumab and chemotherapy
(either as primary systemic or adjuvant treatment) is
considered the standard of care in patients with this
biologically aggressive subtype of breast cancer.
Although this evidence has led to unequivocal im-
provements in outcomes for the vast majority of patients
with HER2-positive disease, the question remains as to
whether there is a place for anti-HER2 therapy without
chemotherapy in individually selected patients with EBC
[7]. One major reason for this uncertainty is the fact that
particular patient subgroups were underrepresented in
the pivotal trials, including elderly patients [8, 9], those
with significant concurrent disease, and those with small
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or low-risk tumors. In the latter subgroup, HER2-tar-
geted therapy seems to be principally indicated, as sev-
eral retrospective studies have shown that HER2
positivity leads to an unfavorable prognosis in patients
with small cancers that are otherwise considered low
risk [7, 10–13]. However, in view of the generally low
rate of relapse events in these patients, chemotherapy-
induced toxicity remains a major concern, leading to the
question as to whether trastuzumab monotherapy is an
adequate alternative option [7]. Hence, the issue of adju-
vant trastuzumab monotherapy has repeatedly been dis-
cussed at international consensus meetings, resulting in
weak recommendations and the recurrent request for
randomized clinical trials. Unfortunately, such trials are
difficult to perform due to the limited cohort size and
the predictably low event rate. We therefore decided to
approach this question within the framework of our
database of about 4000 patients with EBC receiving
trastuzumab.
This observational study [14] was started immediately
after marketing authorization was received for Herceptin™
(trastuzumab) treatment in EBC. Its purpose was to obtain
real-world evidence on routine usage of trastuzumab in
Germany. As this was a non-interventional study with no
criteria concerning patient inclusion or treatment (apart
from trastuzumab), the database included patients who
were receiving trastuzumab without any cytotoxic
treatment. This offered the opportunity to analyze
outcomes in this subgroup and compare them with
patients treated according to the standard approach, both
by crude comparison and by application of a propensity
score method to account for the assumed presence of
selection bias.
Methods
Patient population and methods of observation
Details of the organizational and legal framework of this
non-interventional study (Roche ML20315), the selec-
tion criteria for inclusion in the observation procedure,
and the scope of the documentation have been described
previously [14]. In general, patients were treated and
their disease course was assessed according to routine
practice at the treating institution. Findings were
prospectively documented on standardized case report
forms. Data on treatment toxicity were mainly collected
throughout the duration of adjuvant therapy, i.e. up to
12 months. The study started in 2006 and database lock
for the analyses presented here was October 2013.
Endpoint evaluation and statistical analyses
Relapse-free survival (RFS) and overall survival (OS)
were calculated as the time between the baseline assess-
ment before the first trastuzumab administration and
the respective event. Surviving patients (without relapse
for RFS) were censored at the last valid observation
point. Event-related endpoints were analyzed using
Kaplan-Meier methodology, with 95% confidence inter-
vals (CIs) for event-free proportions at specific time
points. Univariate analyses comparing the treatment
subgroups were performed using the log-rank test, while
hazard ratios (HRs) with 95% CIs were derived from
Cox proportional hazards models [15]. In order to
analyze the association between patient characteristics
and the decision to withhold chemotherapy, t tests,
Fisher’s exact tests, or appropriate trend tests for or-
dered categories were applied. All factors with an associ-
ated P-value <0.1 in univariate analysis were included in
a multivariable logistic regression model.
Propensity score analysis [16], adjusting for selection
bias when comparing the treatment subgroups with
respect to RFS, was performed using the following pro-
spectively planned steps: (1) covariate selection; (2) as-
sessment of covariate balance before matching; (3)
estimation of propensity scores by fitting a logistic
regression model and matching procedure with a chosen
sample size ratio of 1:1; (4) assessment of covariate bal-
ance after propensity score matching; and (5) estimation
of the treatment effect with a log-rank test, stratified by
matched pairs, with RFS as the primary endpoint. As
sensitivity analyses, unstratified methods were also ap-
plied because accounting for matching in time-to-event
endpoints remains controversial [17, 18]. The R statis-
tical software (R Foundation for Statistical Computing;
https://www.r-project.org; Version 3.0) and its “match-
it” package were used.
All statistical analyses were of an exploratory nature,
with P ≤ 0.05 termed significant, without any adjust-
ments for multiplicity applied. All reported P-values are
two-sided.
Results
Baseline and treatment characteristics of patients with
and without chemotherapy
Between September 2006 and July 2011, a total of 3940
eligible patients with HER2-positive breast cancer were re-
cruited, 3935 of whom could be unequivocally categorized
into groups with (n = 3703; 94%) or without (n = 232; 6%)
any sequential or concurrent (neo)adjuvant chemotherapy.
Patient and tumor characteristics are shown in Table 1.
Patients receiving no chemotherapy were almost
3 years older on average (P = 0.0008) and more often
presented with worse performance status (P < 0.0001)
than those who received chemotherapy. In contrast,
tumor-related characteristics such as TNM staging or
hormone receptor status (P = 0.20) differed only margin-
ally between the cohorts. Only poorly differentiated
histology showed a moderate association with
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administration of the more aggressive therapy approach
(P = 0.028).
The administration of additional adjuvant endocrine
treatment was equally common in both patient groups,
but radiotherapy was more often omitted in patients who
did not receive chemotherapy (P < 0.0001). No differences
were detected between patients with and without chemo-
therapy with respect to trastuzumab exposure, with mean
initial doses of 7.1 and 7.2 mg/kg body weight, mean num-
ber of cycles of 18.4 and 17.9, and mean duration of anti-
body therapy of 50.5 and 50 weeks, respectively.
Multivariable analysis of treatment decision
The significant parameters in the univariate analysis were
included in a logistic regression model with the chosen
treatment category as the dependent variable; all retained
their independent level of association (Table 2). There is
an obvious strong correlation between the decision to
treat a patient with chemotherapy and the decision to use
radiotherapy. Therefore a second regression analysis was
done using a model that excluded the radiotherapy factor;
it yielded almost unchanged results for the other factors.
For the same reason, irradiation was not included in the
propensity score procedure (see below).
Trastuzumab-related toxicity
Among the patients receiving chemotherapy, adverse reac-
tions related to cardiac function (all severity grades) were
reported in 154/3703 cases (4.2%), with 93 (2.5%) assessed
as grade 2–4 (Common Terminology Criteria for Adverse
Events V.3). The corresponding numbers in the cohort
receiving no chemotherapy were 5/232 (2.2%) and 4/232
(1.7%), respectively. The incidence of a pathological car-
diac status during the baseline visit (detected by any type
of cardiac monitoring) was similar between the two
groups (7% and 6% in those receiving and not receiving
chemotherapy, respectively). At the end of adjuvant treat-
ment the proportion was 8% in both groups. However, the
general recommendations for heart function assessment
were not followed in a considerable number of patients.
The rate of patients having echocardiography was only
around 60% per three-month time interval [14]. Other
presumed adverse drug reactions of severity grade 3/4
were rare in the monotherapy group: two cases of cardiac
arrhythmia, two cases of dyspnea or other lung toxicity,
and one patient with elevated liver enzymes.
Long-term outcome: Crude analysis
A total of 452 relapse-free survival events were observed
before the database lock. In the chemotherapy group,
the RFS rate was 90% (95% CI 89–92%) at 3 years and
83% (95% CI 81–85%) at 5 years. The corresponding
rates were distinctly lower in the cohort receiving no
chemotherapy: 84% (95% CI 78–89%) and 80% (95% CI
74–87%), respectively (Fig. 1a). The difference between
treatment groups was statistically significant: HR 1.49
(95% CI 1.06–2.09; P = 0.022). A similar pattern was
observed for OS, although with only marginally non-sig-
nificant inferiority for the group receiving no chemo-
therapy, based on a total of 248 reported deaths (HR
1.56; 95% CI 1.00–2.44; P = 0.052) (Fig. 1b). The 3- and
5-year OS rates were 96% (95% CI 96–97%) and 90%
(95% CI 89–92%) with chemotherapy, and 93% (95% CI
88–97%) and 87% (95% CI 81–93%) without chemother-
apy, respectively.
Table 1 Patient and tumor characteristics
Characteristic Chemotherapy No
chemotherapy
P-value
(n = 3703) (n = 232)
Age, years
Mean (range) 55.6 (20–100) 58.3 (27–87) 0.0008
< 60, n (%) 2298 (62) 128 (55)
60– 69, n (%) 971 (26) 58 (25)
≥ 70, n (%) 461 (12) 46 (20)
ECOG performance status, n (%)
0 2301 (63) 108 (47) <0.0001
1 1298 (35) 113 (50)
2–4 61 (2) 7 (3)
Primary tumor stage, n (%)
pT1/is 1750 (50) 114 (51) 0.73
pT2-4 1776 (50) 110 (49)
Lymph node stage, n (%)
pN0 1936 (52) 126 (54)
pN1 1003 (27) 53 (23)
pN2 411 (11) 28 (12)
pN3 259 (7) 13 (6)
NX 82 (2) 12 (5)
No. of nodes involved, mean
± SD
2.2 ± 4.7 2.3 ± 5.1 0.63
Grading, n (%)
Grade 1/2 1731 (47) 123 (55) 0.028
Grade 3 1927 (53) 101 (45)
Hormone-receptor status, n (%)
ER positive 2217 (60) 145 (62)
PgR positive 1857 (50) 133 (57)
Either ER or PgR positive 2332 (63) 156 (67) 0.20
Additional adjuvant treatment, n (%)
Endocrine therapy 2079 (56) 131 (56) 0.99
Radiotherapy 2897 (78) 146 (63) <0.0001
Total patient numbers may deviate from n = 3935 because of missing values for
some characteristics
ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, PgR progesterone
receptor, SD standard deviation
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Long-term outcome: Propensity score analysis
Owing to the very high number of patients receiving
chemotherapy, 204 monotherapy patients with a
complete set of covariates available could be matched
with 204 control patients, achieving perfectly balanced
distributions for age (≥65 years: 35%), T stage (pT2–4:
51%), N stage (pN+: 43%), grading (grade 3: 46%), hor-
mone receptor status (positive: 68%), and performance
status (ECOG 0: 48%). As was expected, these propor-
tions were very close to those described for the entire
cohort without chemotherapy (Table 1).
Figure 2a shows the RFS results for the matched sam-
ples, with an HR of 1.41 (95% CI 0.86–2.31; P = 0.17) in
the unstratified analysis, and HR 1.49 (95% CI 0.88–2.52;
P = 0.14) after stratification of the matched pairs. For OS,
the corresponding results were HR 1.61 (95% CI 0.81-
Logrank test: p = 0.022
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without chemotherapy: n = 232, 36 events
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140
months
0.0
0.2
0.4
0.6
0.8
1.0
Logrank test: p = 0.022
with chemotherapy: n = 3703, 416 events
without chemotherapy: n = 232, 36 events
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140
months
0.0
0.2
0.4
0.6
0.8
1.0
ra
te
 w
ith
ou
t e
ve
nt
ra
te
 w
ith
ou
t e
ve
nt
Fig. 1 Kaplan-Meier plots of (a) relapse-free survival and (b) overall survival in patients with early breast cancer receiving adjuvant trastuzumab
with or without chemotherapy
Table 2 Multivariable regression analysis of factors associated
with treatment category
Factora Odds ratiob [P-value]
Multivariable
model 1c
Multivariable
model 2d
Age: <65 vs ≥65 years 1.51 [P = 0.0056] 1.57 [P = 0.0020]
ECOG performance: 0 vs 1–4 1.80 [P = 0.00003] 1.84 [P = 0.00001]
Grading: Grade 1/2 vs grade 3 0.77 [P = 0.062] 0.77 [P = 0.058]
Radiotherapy: no vs yes 0.53 [P = 0.00002] –
ECOG, Eastern Cooperative Oncology Group
aFirst group mentioned is reference; − = not in model. bA value >1.0 indicates
a higher probability of receiving Herceptin treatment without chemotherapy,
as compared to reference group. cIncluding radiotherapy in the analysis.
dExcluding radiotherapy from the analysis
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3.22; P = 0.17) and HR 2.35 (95% CI 1.05–5.25; P = 0.033)
(Fig. 2b). The Kaplan-Meier curves and HRs did not differ
qualitatively from the results of the crude analysis, sug-
gesting that the superiority of the combined treatment is
not an artifact caused by patient-selection bias. The wider
CIs and larger P-values are an inevitable consequence of
the limited number of observed events that remain after
the matching procedure.
Discussion
In the initial treatment of patients with HER2-positive
breast cancer, administration of a specific agent targeting
this epitope is almost universally indicated, independent
from tumor stage and patient-defined characteristics,
such as age. Focusing on the volume of available
evidence, current treatment guidelines almost exclusively
recommend the use of combination regimens of HER2-
targeted therapy with either chemotherapy or a second
targeted drug [2]. However, the efficacy of trastuzumab
monotherapy was proven early in its clinical develop-
ment program [7], even in heavily pretreated patients
[19, 20]. (Likewise, the addition of trastuzumab to endo-
crine agents in patients with hormone receptor-positive
disease was shown to be beneficial [21].) The use of tras-
tuzumab monotherapy in the adjuvant setting, which is
frequently mentioned as an alternative option, can only
rely on analogy to this evidence derived from the ad-
vanced or neo-adjuvant breast cancer setting [7].
In order to analyze the actual prevalence of this treat-
ment approach in routine clinical practice and to gain
insight into its clinical efficacy, we screened the database of
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Fig. 2 Kaplan-Meier plots of (a) relapse-free survival and (b) overall survival in propensity score matched patients with early breast cancer receiving
adjuvant trastuzumab with or without chemotherapy
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our German observational study and found a small but
considerable subgroup of patients who received trastuzu-
mab without chemotherapy. This contrasts to other real-
life studies from the Netherlands and UK, which reported
no or minimal numbers of such cases [22, 23]. Our data
show that the decision to take this treatment approach is
clearly associated with expected characteristics, such as
older age or worse general health status, and less aggressive
histology, rather than tumor stage. These results from real-
world data reflect findings for hypothetical cases presented
to US oncologists in a survey asking for treatment recom-
mendations in older adults with HER2-positive EBC [24].
Although these characteristics show distinct and statis-
tically significant trends of selection, they do not reflect
a clearly defined subpopulation of our total cohort. One
major limitation of our study is that our documentation
did not include any information on the individual rea-
sons for not administering chemotherapy. Obtaining this
information was prohibited for legal reasons, as includ-
ing this question on the record form would have implied
use of a treatment option that did not comply with the
trastuzumab marketing authorization, which is not
allowed for this type of observational study in Germany.
Nevertheless, we assume that a large proportion of our
trastuzumab monotherapy cohort consists of patients who
refused to be treated with cytotoxic chemotherapy.
Publications on this topic are sparse [25], but in an
American interview-based regional survey of 119 women
who did not receive guideline-recommended adjuvant ther-
apy, patient refusal was the reported reason for 31% [26].
Long-term outcome after trastuzumab therapy without
chemotherapy proved to be in an acceptable range, with
an RFS rate of 80% after 5 years. However, in univariate
comparisons against the cohort receiving chemotherapy,
an advantage for the more aggressive approach was
detected for both RFS and OS. We accounted for the
presumed presence of selection bias by using a propen-
sity score matching technique. This approach led to
efficacy results (as reflected by HRs) that were compar-
able with the findings of the univariate analysis.
To gain an indication of the utility of trastuzumab
monotherapy, we can compare our results against histor-
ical series of patients with HER2-positive breast cancer
who did not receive adjuvant chemotherapy or trastuzu-
mab. For example, a large cohort of 965 patients with small
breast cancer tumors (T1a/bN0M0) from the MD
Anderson Center had a 5-year RFS rate of only 77% [12].
Indirect comparisons (with the usual caveats) against our
RFS estimate of 80% suggest considerable benefit from
trastuzumab monotherapy. This benefit becomes more ob-
vious when considering that in our cohort approximately
50% were T stage ≥2 and 41% were node positive, while
proportions of hormone receptor positivity and endocrine
treatment were roughly similar between the two studies.
Conclusions
In conclusion, trastuzumab plus chemotherapy should
remain the preferred option in all patients with HER2--
positive EBC and an indication for adjuvant treatment.
However, a limited proportion of patients will need an
alternative treatment strategy, either because of contra-
indications or patient preference. In these selected
patients, trastuzumab monotherapy, eventually
combined with endocrine therapy, might be a reasonable
option offering favorable long-term outcomes by
addressing the high-risk profile associated with
HER2-positivity.
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